Mivelsiran Shows Promise in Early Alzheimer's, BHV-7000 Enters Phase 2/3 for Focal Epilepsy
Key Insights
Early-stage data on mivelsiran, an RNA therapeutic, shows encouraging results for treating patients with early Alzheimer's disease.
Biohaven (search) has initiated a phase 2/3 trial to evaluate BHV-7000, a potassium inhibitor, as a potential antiseizure medication for focal epilepsy (search).
Mirdametinib, an investigational treatment for neurofibromatosis (search) type 1-associated plexiform neurofibromas, is being prioritized by SpringWorks Therapeutics.
Mivelsiran, an RNA therapeutic being developed for early-stage Alzheimer's disease, has shown encouraging early-stage data. According to Sharon Cohen, MD, FRCPC, medical director of the Toronto Memory Program at the University of Toronto, an ongoing phase 1 study is assessing the drug's potential in this patient population.
BHV-7000 for Focal Epilepsy
Biohaven (search) has commenced a phase 2/3 clinical trial to investigate BHV-7000, a potassium inhibitor, for the treatment of focal epilepsy (search). Aliza Alter, MD, a pediatric neurologist at the Institute of Neurology in Livingston, New Jersey, commented on the newly initiated study, highlighting its potential as a novel antiseizure medication.
Mirdametinib for Neurofibromatosis
SpringWorks Therapeutics is prioritizing the development of mirdametinib, a treatment for both adult and pediatric patients with neurofibromatosis (search) type 1-associated plexiform neurofibromas. Jim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, discussed the potential of mirdametinib in advancing neurofibromatosis care.
Ravulizumab and NMOSD Management
Michael Levy, MD, PhD, presented 138-week data on ravulizumab for NMOSD (search), focusing on long-term relapse rates, and shared practical tips for effective NMOSD management in clinical settings. The data suggests sustained efficacy of ravulizumab in reducing relapse rates over the long term.